ERBB2 and bronchiolitis obliterans syndrome: Among subjects with BO, none showed HER-2/neu or TOPOIIα amplification or chromosome 17 aneusomy, and almost none had moderate to complete membranous immunoreactivity for HER-2 protein expression (immunohistochemistry) (score 2 or 3) or >50% TOPOIIα protein expression (immunohistochemistry) (quartiles 3–4).